Avon's Breast Cancer Crusade to Offer 'Pink Ribbon' Pens

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

NEW YORK--Avon's Breast Cancer Awareness Crusade, which has raised $10 million through the sales of its $2 pink ribbon pin, has now introduced a pink-enameled ballpoint pen. The new pen, which bears the ribbon motif on its clip, will be available in October, 1995, at a cost of $3.

NEW YORK--Avon's Breast Cancer Awareness Crusade, which has raised$10 million through the sales of its $2 pink ribbon pin, has nowintroduced a pink-enameled ballpoint pen. The new pen, which bearsthe ribbon motif on its clip, will be available in October, 1995,at a cost of $3.

The pink ribbon has been selected by the breast cancer communityas the international symbol of hope and support for those affectedby breast cancer.

Proceeds from pen sales, as with ongoing sales of the pink ribbonpin, will go toward supporting community-based programs acrossthe country. These programs are dedicated to increasing awarenessof breast cancer and improving access to early detection services,especially for lower income, minority, and older women, and otherswho are medically underserved.

Woman-to-Woman Effort

Avon's Breast Cancer Awareness crusade has been working sinceOctober, 1993, to educate women about breast health. The crusadehas funded more than 125 community programs across the UnitedStates. In addition, Avon representatives have distributed 32million educational brochures in a woman-to-woman outreach effort.

Early on, Avon developed an innovative public/private/nonprofitpartnership with the YWCA of the USA, Centers for Disease Controland Prevention (CDC), National Alliance of Breast Cancer Organizations(NABCO), and National Cancer Institute, with the goal of improvingwomen's access to breast cancer services.

For information about the crusade and how to purchase the pinkribbon pen, call 1-800-FOR-AVON for the name of a neighborhoodAvon representative.

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Related Content